Fluocortolone pivalate is a synthetic corticosteroid used primarily in the treatment of inflammatory skin conditions and hemorrhoidal disease, often in combination with other agents such as local anesthetics. It exerts anti-inflammatory, antipruritic, and vasoconstrictive effects by suppressing the release of inflammatory mediators in affected tissues. The drug has been widely used in topical formulations, particularly in Europe, for managing conditions such as eczema, dermatitis, and anorectal inflammation.
Unlike systemic therapies for infectious diseases, fluocortolone pivalate is designed for localized action with minimal systemic absorption when applied correctly. Its clinical use has focused on improving tolerability and efficacy in topical corticosteroid therapy, especially in sensitive skin regions where long-term steroid use requires careful dose control.
BRAND NAMES
Ultraproct (Bayer)
Most widely known brand
Available as ointment and suppositories
Contains fluocortolone pivalate (often combined with fluocortolone caproate + cinchocaine for stronger anti-inflammatory and local anesthetic effects)
Ultraproct N (in some markets)
Variant formulations depending on country.
MECHANISM OF ACTION
Fluocortolone pivalate is a synthetic glucocorticoid that exerts its effects by binding to intracellular glucocorticoid receptors and influencing gene transcription. After penetrating target cells, the drug–receptor complex translocates to the nucleus, where it regulates the expression of anti-inflammatory proteins and suppresses pro-inflammatory genes.
PHARMACOKINETICS
Absorption:
Fluocortolone pivalate is a topical glucocorticoid that is absorbed through the skin in small, variable amounts depending on the formulation, skin integrity, and site of application. Intact skin limits systemic absorption, while inflamed or damaged skin may increase penetration.
Distribution:
After dermal absorption, fluocortolone pivalate binds extensively to plasma proteins, mainly albumin and corticosteroid-binding globulin. Due to its topical nature, systemic distribution is limited, and tissue concentrations are primarily localized to the site of application.
Metabolism:
Fluocortolone pivalate is rapidly hydrolyzed after absorption to its active form, fluocortolone, and further metabolized in the liver.
Elimination:
Metabolites are primarily eliminated through the kidneys via urine, with a smaller proportion excreted in bile and feces. Because systemic absorption is low, overall elimination is minimal under normal topical use conditions.
PHARMACODYNAMICS
Fluocortolone pivalate is a synthetic glucocorticoid that binds to intracellular glucocorticoid receptors and regulates gene transcription. It suppresses the expression of pro-inflammatory mediators such as cytokines, prostaglandins, and leukotrienes while inducing anti-inflammatory proteins like lipocortin (annexin-1), which inhibits phospholipase A₂ activity.
ADMINISTRATION
Fluocortolone pivalate is administered topically, most commonly as rectal ointments, creams, or suppositories. It is applied directly to the affected area in conditions such as hemorrhoids, anal fissures, and inflammatory anorectal disorders. In combination products like Ultraproct, it is often paired with a local anesthetic to provide both anti-inflammatory and analgesic effects.
DOSAGE AND STRENGTH
Fluocortolone pivalate is used as a topical corticosteroid, and its dosage depends on the formulation (cream, ointment, or rectal preparation) and severity of the condition. In combination products such as Ultraproct, it is commonly applied once or twice daily to the affected area in a thin layer.
DRUG INTERACTIONS
Clinically significant systemic drug interactions are rare due to minimal absorption of fluocortolone pivalate when used topically. However, concurrent use with other corticosteroids (topical or systemic) may increase the risk of cumulative steroid effects if used in high doses or over large surface areas.
FOOD INTERACTIONS
There are no known food interactions with fluocortolone pivalate because it is administered topically or rectally and does not undergo meaningful gastrointestinal absorption.
CONTRAINDICATIONS
Fluocortolone pivalate is contraindicated in patients with hypersensitivity to the drug or any formulation component. It should not be used in untreated bacterial, viral, or fungal infections at the application site unless appropriate antimicrobial therapy is also given. Long-term use is avoided in conditions where skin or mucosal atrophy could worsen outcomes.
SIDE EFFECTS
Local irritation at the application site
Burning sensation
Itching (pruritus)
Dryness of skin or mucosa
Redness (erythema)
OVER DOSAGE
Overdosage with fluocortolone pivalate is uncommon because it is a topical corticosteroid with limited systemic absorption. When excessive amounts are applied or used over large surface areas for prolonged periods, the effects are usually local rather than systemic.
TOXICITY
Toxicity is rare due to low systemic absorption. However, prolonged or high-dose use may lead to local tissue damage such as skin atrophy or mucosal thinning. In rare cases of extensive use, systemic corticosteroid effects such as hypothalamic-pituitary-adrenal (HPA) axis suppression may occur.
